Average Price Target: $8.00
▲ +52.09% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Agenus in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 52.09% upside from the last price of $5.26.
The current consensus among 3 polled investment analysts is to buy stock in Agenus. This Buy consensus rating has held steady for over two years.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.